TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* probing depth of 7mm or greater at baseline~* following debridement, 4mm or greater vertical bone defect depth with at least one intact bony wall~* sufficient keratinized tissue to allow complete tissue coverage of the defect~* a radiographic base of the defect at least 3mm coronal to the apex of the tooth~* no evidence of localized aggressive periodontitis~* smoke less than 1 pack of cigarettes per day~Exclusion Criteria:~* failure to maintain adequate oral hygiene~* pregnant women or women intending to become pregnant~* history of oral cancer within last 6 months or HIV~* history within last year of periodontal surgery on study tooth~* study tooth mobility greater than 2~* study tooth exhibiting a class 3 furcation defect~* signs of untreated acute infection at the surgical site, apical pathology, root fracture, severe root irregularities, cemental pearls, cementoenamel junction (CEJ) projections not easily removed, untreated carious lesions at the CEJ or on the root surface, subgingival restorations or restorations with open margins at or below CEJ~* history within 6 months of weekly or more frequent use of smokeless chewing tobacco, pipe or cigar smoking, or more than 20 cigarettes a day~* allergy to yeast derived products~* investigational therapy within 30 days of surgery

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- B-TCP +buffer (Type: ACTIVE_COMPARATOR): Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.
- B-TCP + 0.3 mg/ml rhPDGF-BB in buffer (Type: EXPERIMENTAL): Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
- B-TCP + 1.0 mg/ml rhPDGF-BB in buffer (Type: EXPERIMENTAL): Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes~* Fasting c-peptide below lower limit of normal fasting range~* Duration of type 1 diabetes for at least 12 months~* Current treatment: Basal - bolus regimen for at least 4 months with intermediate or long-acting insulin once, twice or three times daily as basal insulin and 3-4 premeal insulin aspart or lispro injections~* HbA1c maximum 9.0% (using Biorad Variant method)~* Able and willing to perform self-monitoring of blood glucose~* Basal insulin requirement at least 30% of the total daily insulin dose~* BMI (body Mass Index) maximum 35 kg/m\^2~Exclusion Criteria:~* Proliferative retinopathy or maculopathy requiring acute treatment~* Total daily insulin dose above 1.4 IU/kg/day~* Known unawareness of hypoglycaemia~* Impaired hepatic function~* Impaired renal function~* Cardiac problems~* Uncontrolled, treated/untreated hypertension~* Known or suspected allergy to trial product or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Detemir (Type: EXPERIMENTAL): None
- NPH (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Confirmatory Study Confirming Performance of a New Intermittent Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male~2. Is at least 18 years of age and has full legal capacity~3. Has given written informed consent~4. Has signed letter of authority (only DK)~5. Has used clean intermittent self-catheterisation (CISC) for at least the last 3 months~6. Has used intermittent catheterisation as the only bladder emptying method for at least the last 3 months~7. Self-catheterise using Coloplast SpeediCath Flex or Hollister VaPro catheters, CH12 or CH14, for at least 3 months prior to inclusion~8. Ability (assessed by investigator) and willingness to adhere to a 2-month study period~Exclusion Criteria~1. Participation in any other clinical study during this investigation~2. Previous participation in this study~3. Symptoms of urinary tract infection as judged by the investigator (rescheduling allowed within recruitment period for LPI)~4. Individuals with history, suspected or showing signs of producing urine with excessive amount of mucus or large/clustered sediments or debris~5. Any known allergies towards ingredients in the investigational device

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Investigational device - intermittent catheter with micro-hole zone (Type: EXPERIMENTAL): Ready-to-use, sterile, hydrophilic coated intermittent male catheter (sizes CH12 and CH14) with a flexible tip and a micro-hole zone for urinary drainage. The investigational device is for single use.
- Comparator device - standard intermittent catheter (Type: ACTIVE_COMPARATOR): Single-use, hydrophilic coated intermittent male catheters (sizes CH12 and CH14) with sleeves: SpeediCath Flex, VaPro, VaPro Pocket, VaPro Plus and VaPor Plus Pocket.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus for more than 12 months~* Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion for more than 12 months~* Body mass index (BMI) between 18.0-28.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to trial start~* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)~* Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Formulation A (Type: EXPERIMENTAL): None
- Formulation B (Type: EXPERIMENTAL): None
- Insulin Aspart (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: P4 (Pregabalin for Peripheral Posttraumatic Pain)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Posttraumatic Peripheral Neuropathic Pain (NeP) syndrome, including post-surgical NeP, NeP due to peripheral nerve injury, and phantom limb pain, confirmed by a qualified pain specialist and persisting for a minimum of 3 months following the traumatic event~Exclusion Criteria:~* Subjects whose posttraumatic neuropathic pain is due to Complex Regional Pain Syndrome (CRPS, Type I or Type II)~* NeP not due to trauma, and not peripheral pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glutamatergic Modulation of Cocaine-related Deficits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Active free-base cocaine dependence (at least 4 days of use over the past month, with at least 1 use per week); if the participant uses through another route (IN, IV), then the FB route is dominant (\> 80% of occasions).~2. Physically healthy~3. No adverse reactions to study medications~4. 21-52 years of age~5. Normal body weight~6. Responsive to drug cues~7. Capacity to consent~Exclusion Criteria:~1. Seeking treatment or abstinence~2. DSM IV criteria for substance dependence (other than methamphetamine, cocaine, cannabis, or nicotine), or DSM IV criteria for abuse of ketamine or lorazepam~3. DSM-IV criteria for other Axis I psychiatric illness that may make participation hazardous such as schizophrenia, schizoaffective disorder, psychosis NOS, MDD, psychosis secondary to substances, or bipolar disorder~4. Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders~5. Current suicide risk or a history of suicide attempt within the past 2 years~6. Current use of prescribed psychotropic medication~7. Pregnancy, nursing, or had a baby within the past 6 mo.~8. Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.~9. Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (\>140/90), anemia, active hepatitis or other liver disease, or diabetes~10. Bad reaction/experience with prior exposure to ketamine or lorazepam~11. History of significant violence~12. First degree relative with a psychotic disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 52 Years
- Healthy Volunteers: f

Study Arms:
- K1 (Type: EXPERIMENTAL): Ketamine 0.41 mg/kg infused over 52 min (K1)
- K2 (Type: EXPERIMENTAL): Ketamine 0.71 mg/kg infused over 52 min (K2)
- LZP (Type: EXPERIMENTAL): Lorazepam 2 mg infused over 52 minutes (LZP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 months to 68 months inclusive (recommended 3 to 8 months for Groups A and B; 2 months for Group C) on the day of inclusion~* Informed consent form signed by the parent(s) or other legal representative~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Fever ≥ 37.5°C (axillary temperature) on the day of inclusion~* Any serious disease whether acute or chronic~* Past or current medical history of Guillain-Barre syndrome, acute thrombocytopenic purpura or encephalopathy~* History of diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b infections~* History of a life threatening reaction to a vaccine containing the same substances of the study vaccine~* History of anaphylaxis to any of the study vaccine components~* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis or Haemophilus influenzae type b infections with a trial vaccine or another vaccine~* Congenital or current acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Participation in another clinical trial preceding the trial inclusion~* Planned participation in another clinical trial during the present trial period~* Blood or blood-derived products received in the past or current or planned administration during the trial (including immunoglobulins)~* Any vaccination with live vaccines within the past 27 days preceding the first trial vaccination~* Any vaccination with inactivated vaccines within the past 6 days preceding the first trial vaccination~* Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or HIV infection~* Subject ineligible according to the Investigator's clinical judgment~* Identified as employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family member (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 68 Months
- Healthy Volunteers: t

Study Arms:
- Group A (SP0204) (Type: EXPERIMENTAL): Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously
- Group B (control) (Type: ACTIVE_COMPARATOR): Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously
- Group C (Type: EXPERIMENTAL): Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Movicol in Childhood Constipation (ProMotion Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients that, in the opinion of the investigator, are constipated/faecally impacted as to require hospital stay to treat and/or relieve the impaction~* children aged 2 - 11 years old inclusive~* patients of either sex~Exclusion Criteria:~Patients with~* intestinal perforation or obstruction~* severe inflammatory conditions of the intestinal tract~* uncontrolled renal/hepatic/cardiac diseases~* uncontrolled endocrine disorder(s)~* any neuromuscular condition affecting bowel function~* hypersensitivity to lactulose or PEG or other constituent of Movicol~* patients who have taken any investigational drug in the three months~* patients or patients whose parents would in the opinion of the investigator are unable to comply with requirements of the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Expectations on Negative Affect, Perceived Cognitive Effort, and Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of performing experimental tasks (e.g., are able to read, can tolerate the maximum level of thermal pain stimuli).~* Fluent or native speakers of English~Exclusion Criteria:~* Contraindications to magnetic resonance scanning (e.g., metal in body, claustrophobia, pregnancy)~* Substance abuse within the last six months~* Current or recent history of pathological pain~* Current or recent history of neurological disorders~* Currently or recent history of chronic pain~* Left-handed only

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cue-established expectations (Type: EXPERIMENTAL): Prior to experiencing the stimuli from three tasks (somatic pain/cognitive effort/vicarious pain), the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no effort to strongest effort of any kind. Subsequently, participants report expectation ratings and outcome ratings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) \<50,000 copies/mL~* Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization~* Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.~Exclusion Criteria:~* History of opportunistic infections within 12 months before the first study vaccination~* History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy~* History of invasive pneumococcal disease~* Known hypersensitivity to any vaccine component~* Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease~* Coagulation disorder contraindicating intramuscular vaccination~* History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* Female participant: positive urine or serum pregnancy test~* Prior administration of any pneumococcal vaccine~* Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment~* Received immunosuppressive therapy~* Received a blood transfusion or blood products within 6 months of enrollment~* Participated in another clinical study of an investigational product within 2 months of enrollment~* Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 years old, of both genders;~* Patients with diabetes mellitus type I or type II;~* Macular edema presence of clinically significant diabetic in their mixed or diffuse;~* Visual acuity worse than 20/40 corrected (\< 68 letters ETDRS)~* Glycated hemoglobin ≤ 11%;~* Systolic and diastolic blood pressure \< 170 and \< 100 mmHg, respectively;~* Women not pregnant;~* Free and informed consent term signed the screening visit;~* Ability to adhere to the visits.~Exclusion Criteria:~* Failure to comply with any of the inclusion criteria;~* Treatment for DME within the prior 3 months;~* Vitreoretinal traction within 1 disc diameter (DD) of the fovea, clinically confirmed or with OCT;~* Atrophy or fibrosis surrounding the fovea;~* Any level of cataract;~* Vitreous hemorrhage or any opacity means;~* Eye disease related to diabetic retinopathy that can derail the central vision (eg Age Macula Degeneration, chorioretinitis scar, ...)~* Best-corrected visual acuity to 20/40 (\> 68 letters ETDRS)~* Inability to understand the treatment and the term of consent;~* Debilitating systemic disorders that preclude the patient's admission to the study, according to the clinical judgment of the investigator;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: EXPERIMENTAL): Group 1 - 21 eyes treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0, 6,12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
- Sham (Type: SHAM_COMPARATOR): Group 2 - 20 eyes treated with sham injection at weeks 0 and 6; and intravitreal bevacizumab injection(1.25mg) in the weeks 12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete